

Abstract

The present invention relates to the development of an *in vivo* assay system, useful for developing therapeutic options by testing the efficacy of drugs and other substances, said system constituting a novel, fast, and inexpensive *in vivo* assay system wherein, transgenic *Drosophila* harbors human Adenomatous Polyposis Coli gene, a negative regulator of β -catenin.